Visudyne Medicare Settlement: CMS Cmte To Review Occult Lesion Data
Executive Summary
CMS' Medicare Coverage Advisory Committee will review initial data from QLT's Phase III trial of Visudyne (verteporfin) for age-related macular degeneration patients with occult lesions
You may also be interested in...
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B
Visudyne Gets Medicare Cmte. Recommendation For Occult Lesion Coverage
CMS should consider limiting Medicare coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) for age-related macular degeneration and occult lesions with no classic choroidal neovascularization to patients with small lesions, members of a Medicare advisory panel said